Leukemic Presentation of ALK-negative Anaplastic Large Cell Lymphoma in a Patient with Myelodysplastic Syndrome

被引：5

作者：

Tanaka, Hiroaki ^{[2
]}

Ohwada, Chikako ^{[1
]}

Hashimoto, Shinichiro ^{[2
]}

Sakai, Shio ^{[1
]}

Takeda, Yusuke ^{[1
]}

Abe, Daijiro ^{[1
]}

Takagi, Toshiyuki ^{[3
]}

Ohshima, Koichi ^{[4
]}

Nakaseko, Chiaki ^{[1
]}

机构：

[1] Chiba Univ Hosp, Dept Hematol, Chiba, Japan

[2] Oami Hosp, Dept Hematol, Oamishirasato, Japan

[3] Chiba Canc Ctr Hosp, Div Hematol Oncol, Chiba, Japan

[4] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka, Japan

来源：

INTERNAL MEDICINE | 2012年 / 51卷 / 02期

关键词：

anaplastic large cell lymphoma (ALCL); ALK-negative; leukemic manifestation; myelodysplastic syndrome; NON-HODGKIN-LYMPHOMA; PERIPHERAL-BLOOD; TRANSLOCATION; INVOLVEMENT; EXPRESSION; DISEASE; PHASE;

D O I：

10.2169/internalmedicine.51.6146

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 50-year-old woman with a history of aplastic anemia developed cervical lymphadenopathy and atypical lymphocytosis. Atypical cells of lymph nodes were positive for CD3 and CD30 but negative for anaplastic lymphoma kinase (ALK). Bone marrow examination showed trilineage myelodysplasia. She was diagnosed with ALK-negative anaplastic large cell lymphoma (ALCL) with leukemic transformation and myelodysplastic syndrome (MDS) which presumably developed from aplastic anemia. The lymphoma was resistant to intensive chemotherapies, ultimately leading to death. Leukemic presentation of ALK-negative ALCL as an initial manifestation is extremely rare, and the progression of the disease may be influenced by MDS through alteration of immune functions.

引用

页码：199 / 203

页数：5

共 50 条

[21] Progress in the identification of subgroups in ALK-negative anaplastic large-cell lymphoma
Boddicker, Rebecca L.
Feldman, Andrew L.
BIOMARKERS IN MEDICINE, 2015, 9 (08) : 719 - 722
[22] Nursing Practices for a Patient With ALK-Negative Anaplastic Large Cell Lymphoma With a Cancerous Wound: A Case Report
Liu, Mei
Cai, Nina
Du, Meichen
Guo, Juan
WOUND MANAGEMENT & PREVENTION, 2024, 70 (04)
[23] Leukemic phase of primary cutaneous anaplastic large-cell lymphoma (ALK-negative), with downregulation of CD30
Emily Glynn
Andrei R. Shustov
Claire Murphy
Lori Soma
Journal of Hematopathology, 2018, 11 : 45 - 49
[24] ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase"
Lu, Ying
Zhao, Xiaohui
Wang, Endi
Chen, Wei
Huang, Qin
LEUKEMIA RESEARCH, 2010, 34 (04) : 475 - 482
[25] Axillary Lymphadenopathy: An Outstanding Presentation for Breast Implant-Associated ALK-Negative Anaplastic Large Cell Lymphoma
Tardio, Juan C.
Granados, Rosario
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2015, 23 (05) : 424 - 428
[26] Axillary lymphadenopathy: An outstanding presentation for breast implant-associated ALK-negative anaplastic large cell lymphoma
Tardio, J. C.
Granados, R.
VIRCHOWS ARCHIV, 2014, 465 : S100 - S100
[27] Leukemic phase of primary cutaneous anaplastic large-cell lymphoma (ALK-negative), with downregulation of CD30
Glynn, Emily
Shustov, Andrei R.
Murphy, Claire
Soma, Lori
JOURNAL OF HEMATOPATHOLOGY, 2018, 11 (02) : 45 - 49
[28] Primary bone ALK-negative anaplastic T cell lymphoma
Zablocka, T.
Isajevs, S.
Nazarovs, J.
Repnikovs, A.
VIRCHOWS ARCHIV, 2019, 475 : S343 - S343
[29] ALK+ small cell variant of anaplastic large cell lymphoma with leukemic presentation
Jiang, Xianyong
Zhou, Daobin
BLOOD, 2018, 131 (15) : 1764 - 1764
[30] ALK-negative anaplastic large cell lymphoma masquerading as allergic contact dermatitis of the face
Thomas, L.
Cousen, P.
Svec, A.
Robinson, K.
Carmichael, A. J.
BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (04) : E122 - E122

← 1 2 3 4 5 →